Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A43805 | 30835849 | J Food Sci | Extraction Technology Can Impose Influences on Peanut Oil Functional Quality: A Study to Investigate the Lipid Metabolism by Sprague-Dawley Rat Model. | 2019 | Details |
| A43806 | 30835190 | Radiology | Probing the Liver-Heart Axis. | 2019 | Details |
| A43807 | 30835028 | Dig Dis Sci | Disease Burden of Hepatocellular Carcinoma: A Global Perspective. | 2019 | Details |
| A43808 | 30831595 | Ann Intern Med | Web Exclusive. Annals On Call - Nonalcoholic Fatty Liver Disease: A Spectrum of Disorders. | 2019 | Details |
| A43809 | 30831126 | Life Sci | The relevance of pyroptosis in the pathogenesis of liver diseases. | 2019 | Details |
| A43810 | 30825528 | Clin Gastroenterol Hepatol | Establishing an Effective Weight Loss Program in a Community-Based Gastroenterology Practice: The Huron Gastro Experience. | 2019 | Details |
| A43811 | 30821517 | Curr Med Res Opin | Response: non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. | 2019 | Details |
| A43812 | 30819696 | J Lipid Res | Regulation of lipophagy in NAFLD by cellular metabolism and CD36. | 2019 | Details |
| A43813 | 30819009 | Curr Med Res Opin | Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. | 2019 | Details |
| A43814 | 32812926 | Metabol Open | What are the key points in the association between the gut microbiome and nonalcoholic fatty liver disease? | 2019 | Details |
| A43815 | 30816074 | Curr Vasc Pharmacol | Menopause and its Cardiometabolic Consequences: Current Perspectives. | 2019 | Details |
| A43816 | 30805080 | Oxid Med Cell Longev | Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease. | 2019 | Details |
| A43817 | 30794294 | JAMA Netw Open | Considering Bariatric Surgery in Patients With Nonalcoholic Steatohepatitis-Worth the Risk. | 2019 | Details |
| A43818 | 30793706 | Pol Arch Intern Med | Evaluation of adipose tissue and liver radiodensity in overweight or obese patients with nonalcoholic fatty liver disease. | 2019 | Details |
| A43819 | 30791787 | Expert Rev Gastroenterol Hepatol | Non-alcoholic fatty liver disease and cardiovascular risk: an update. | 2018 | Details |
| A43820 | 30791772 | Expert Rev Gastroenterol Hepatol | Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. | 2019 | Details |
| A43821 | 30791762 | Expert Rev Gastroenterol Hepatol | Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease. | 2019 | Details |
| A43822 | 30789748 | Am J Physiol Gastrointest Liver Physiol | Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice. | 2019 | Details |
| A43823 | 30789289 | J Womens Health (Larchmt) | Testosterone Levels in Women: Implications for Fatty Liver and Beyond. | 2019 | Details |
| A43824 | 30785686 | Klin Lab Diagn | [Formation in the phylogenesis of three pulls of cells with expressed different absorption and metabolism of fatty acids. Insulin and medium chains fatty acids.] | 2019 | Details |
| A43825 | 30778234 | Nat Biotechnol | The new liver epidemic. | 2019 | Details |
| A43826 | 30771497 | Clin Gastroenterol Hepatol | Fibroscan for the Rest of Us-How to Incorporate Fibroscan Into Management of Patients With Liver Disease. | 2019 | Details |
| A43827 | 30770439 | Proc Natl Acad Sci U S A | PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin. | 2019 | Details |
| A43828 | 30769360 | Ultraschall Med | What Ultrasound Operators Must Be Well Aware of in a World With Raising Burden of Non Alcoholic Fatty Liver Disease? | 2019 | Details |
| A43829 | 30767680 | Am J Physiol Gastrointest Liver Physiol | Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. | 2019 | Details |
| A43830 | 30766960 | Hepatol Commun | Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. | 2018 | Details |
| A43831 | 30766412 | Fed Pract | Managing the Silent Epidemic of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A43832 | 30763194 | N Engl J Med | Notch and Nonalcoholic Fatty Liver and Fibrosis. | 2019 | Details |
| A43833 | 30763050 | Am Fam Physician | Metformin for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. | 2019 | Details |
| A43834 | 30763014 | J Ultrason | Multifocal fatty liver disease, insulin resistance and carotid atherosclerosis: exploring the interrelated relationship. | 2018 | Details |
| A43835 | 30761212 | Clin Liver Dis (Hoboken) | An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications. | 2018 | Details |
| A43836 | 30754062 | Z Gastroenterol | [Do NAFLD-patients require HCC screening?] | 2019 | Details |
| A43837 | 30744928 | J Clin Densitom | Bone Health in Patients With Liver Diseases. | 2019 | Details |
| A43838 | 30741841 | J Clin Gastroenterol | Thirty Years of Lactobacillus rhamnosus GG: A Review. | 2019 | Details |
| A43839 | 30739262 | Hepatol Int | Serum ferritin as a biomarker for NAFLD: ready for prime time? | 2019 | Details |
| A43840 | 30734689 | Endocr Metab Immune Disord Drug Targets | Silibinin Ameliorates Fructose-induced Lipid Accumulation and Activates Autophagy in HepG2 Cells. | 2019 | Details |
| A43841 | 30734078 | Chirurg | [Metabolic surgery]. | 2019 | Details |
| A43843 | 30721959 | Adv Nutr | Mechanisms of Action of Probiotics. | 2019 | Details |
| A43844 | 30721927 | Am J Clin Nutr | Measure for measure? | 2019 | Details |
| A43845 | 30706731 | Diab Vasc Dis Res | Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. | 2019 | Details |
| A43846 | 30705513 | J Clin Biochem Nutr | 5-Aminolevulinic acid with ferrous iron improves early renal damage and hepatic steatosis in high fat diet-induced obese mice. | 2018 | Details |
| A43847 | 30702486 | J Clin Gastroenterol | A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. | 2020 | Details |
| A43848 | 30700210 | Br J Biomed Sci | Clinicopathological impact of anti-smooth muscle antibodies in patients with non-alcoholic fatty liver disease. | 2019 | Details |
| A43849 | 30689936 | Glycobiology | Hyaluronan histochemistry-a potential new tool to assess the progress of liver disease from simple steatosis to hepatocellular carcinoma. | 2019 | Details |
| A43850 | 30685022 | J Am Coll Surg | What Constitutes Ideal Perioperative Glycemic Control for Preventing Acute Postoperative Hyperglycemia in Surgical Patients with Nonalcoholic Fatty Liver Disease? | 2019 | Details |
| A43851 | 30683616 | Dig Liver Dis | Time to revise the definition of NAFLD: A purist vision. | 2019 | Details |
| A43852 | 30679232 | J Lipid Res | Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. | 2019 | Details |
| A43853 | 30677403 | Cell Mol Gastroenterol Hepatol | Treating Nonalcoholic Fatty Liver Disease From the Outside In? | 2019 | Details |
| A43854 | 30677262 | Obesity (Silver Spring) | Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. | 2019 | Details |
| A43855 | 30675025 | Nat Rev Gastroenterol Hepatol | Panel of 10 serum metabolites shows promise in the non-invasive detection of advanced fibrosis. | 2019 | Details |
| A43856 | 30672769 | J Pediatr Gastroenterol Nutr | Lean Nonalcoholic Fatty Liver Disease: Should It Be Considered in Lean Adolescents With Elevated Liver Enzymes? | 2019 | Details |
| A43857 | 30670473 | J Lipid Res | Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. | 2019 | Details |
| A43858 | 30670274 | Complement Ther Med | Effect of Zataria multiflora on fatty liver disease. | 2018 | Details |
| A43859 | 30670253 | Complement Ther Med | Effect of Zataria multiflora on fatty liver disease. | 2018 | Details |
| A43860 | 30670052 | Lipids Health Dis | Effects of exercise training on Fetuin-a in obese, type 2 diabetes and cardiovascular disease in adults and elderly: a systematic review and Meta-analysis. | 2019 | Details |
| A43861 | 30666860 | J Biol Regul Homeost Agents | Mechanism of high-fat diet-induced non-alcoholic fatty liver disease.. | 2019 | Details |
| A43862 | 30665278 | Gut Liver | It's Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging. | 2019 | Details |
| A43863 | 30664675 | Nat Rev Endocrinol | Potential treatment strategy for NASH. | 2019 | Details |
| A43864 | 30657244 | Liver Transpl | Predicting Outcomes of Liver Transplantation in Patients With Nonalcoholic Steatohepatitis: Pretransplant Renal Function Is Key. | 2019 | Details |
| A43865 | 30654391 | Semin Liver Dis | Extracellular Vesicles in Liver Diseases: Diagnostic, Prognostic, and Therapeutic Application. | 2019 | Details |
| A43866 | 30654277 | J Nutr Biochem | A mix of dietary fermentable fibers improves lipids handling by the liver of overfed minipigs. | 2018 | Details |
| A43867 | 30652529 | Thyroid | Re: "Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis" by Mantovani et al. (Thyroid 2018;28:1270-1284). | 2019 | Details |
| A43868 | 30648604 | Clin Gastroenterol Hepatol | Minding the Gap Between Clinical Trials and Treatment With the Mediterranean Dietary Pattern for Patients With Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A43869 | 30648577 | J Food Drug Anal | Identification of baicalin from Bofutsushosan and Daisaikoto as a potent inducer of glucose uptake and modulator of insulin signaling-associated pathways. | 2018 | Details |
| A43870 | 30642561 | Am J Med | Non-Alcoholic Fatty Liver Disease and Disease Mongering. | 2019 | Details |
| A43871 | 30641759 | Diabetes Metab Syndr | Relationship between glucagon like peptide-1 and non-alcoholic fatty liver disease in diabetic and non-diabetic patients. | 2018 | Details |
| A43872 | 30630119 | Cell Mol Gastroenterol Hepatol | Deletion of C-C Motif Chemokine Ligand 5 Worsens Invariant Natural Killer T-Cell-Mediated Hepatitis via Compensatory Up-regulation of CXCR2-Related Chemokine Activity. | 2019 | Details |
| A43873 | 30629464 | FASEB J | Maternal prebiotic supplementation reduces fatty liver development in offspring through altered microbial and metabolomic profiles in rats. | 2019 | Details |
| A43874 | 30625338 | Toxicol Appl Pharmacol | Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation. | 2019 | Details |
| A43875 | 30617219 | Diabetes | Perilipin 5 Deletion in Hepatocytes Remodels Lipid Metabolism and Causes Hepatic Insulin Resistance in Mice. | 2019 | Details |
| A43876 | 30615269 | Liver Int | Reply to Mantovani: "Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes". | 2019 | Details |
| A43877 | 30615260 | Liver Int | Insights into paediatric non-alcoholic fatty liver disease from genetic variants. | 2019 | Details |
| A43878 | 30615211 | Hepatology | Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. | 2019 | Details |
| A43879 | 30611667 | Hepatobiliary Pancreat Dis Int | Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. | 2018 | Details |
| A43880 | 30610616 | Arch Pharm Res | Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma. | 2019 | Details |
| A43881 | 30609251 | Aging Cell | Reactive oxygen species-induced changes in glucose and lipid metabolism contribute to the accumulation of cholesterol in the liver during aging. | 2019 | Details |
| A43882 | 30604081 | Obes Surg | Crashing NASH in Patients Listed for Bariatric Surgery. | 2019 | Details |
| A43883 | 30581509 | Prz Gastroenterol | Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. | 2018 | Details |
| A43884 | 30576689 | Metabolism | Ectopic lipid deposition mediates insulin resistance in adipose specific 11β-hydroxysteroid dehydrogenase type 1 transgenic mice. | 2018 | Details |
| A43885 | 30570159 | Hepatology | The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis. | 2019 | Details |
| A43886 | 30565101 | Obes Surg | Reply to "Crashing NASH in Patients Listed for Bariatric Surgery". | 2019 | Details |
| A43887 | 30563736 | Nutr Metab Cardiovasc Dis | Role of socio-economic status in observational studies: A study model on non-alcoholic steato-hepatitis (NASH). | 2018 | Details |
| A43888 | 30560337 | Dig Dis Sci | Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth. | 2019 | Details |
| A43889 | 30559444 | Nat Rev Gastroenterol Hepatol | A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. | 2019 | Details |
| A43890 | 30554786 | Lancet | Fibroblast growth factor 21 for non-alcoholic steatohepatitis. | 2018 | Details |
| A43891 | 30553904 | JACC Heart Fail | Heart Failure and Liver Disease: Cardiohepatic Interactions. | 2018 | Details |
| A43892 | 30552380 | Nat Rev Endocrinol | Relieving ER stress to target NASH-driven hepatocellular carcinoma. | 2019 | Details |
| A43893 | 30548562 | Liver Int | Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes. | 2019 | Details |
| A43894 | 30547298 | J Nucl Cardiol | PET imaging of glucose and fatty acid metabolism for NAFLD patients. | 2018 | Details |
| A43895 | 30522511 | Lipids Health Dis | Cordycepin reduces weight through regulating gut microbiota in high-fat diet-induced obese rats. | 2018 | Details |
| A43896 | 30541093 | Am J Clin Nutr | A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandioos study, a randomized trial in overweight subjects. | 2018 | Details |
| A43897 | 30520351 | Int J Surg Pathol | Incidental Hepatic Tissue Obtained via Routine Cholecystectomy. | 2018 | Details |
| A43898 | 30520060 | Hepatology | The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease. | 2019 | Details |
| A43899 | 30503805 | Metabolism | Research developments in metabolism 2018. | 2018 | Details |
| A43900 | 30515858 | Hepatology | Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis. | 2019 | Details |
| A43901 | 30507644 | Eur J Gastroenterol Hepatol | Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease? | 2019 | Details |
| A43902 | 30499884 | J Pediatr Gastroenterol Nutr | Abnormal Liver Enzymes in Fat or Lean Children Should Always Be a Cautionary Tale. | 2019 | Details |
| A43903 | 30498715 | Hepatobiliary Surg Nutr | Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden. | 2018 | Details |
| A43904 | 30498606 | Case Rep Gastrointest Med | Gastrointestinal Bleeding Secondary to Portal Hypertensive Duodenopathy in a Patient with Decompensated Liver Cirrhosis. | 2018 | Details |
| A43905 | 30488630 | Aliment Pharmacol Ther | Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply. | 2018 | Details |